Product Description
HQK-1004 acts by inducing the expression of a gene for a viral protein that is the target of several common anti-viral drugs, including GCV, which eradicate virally infected cells. The gene that makes this target protein is present in EBV infected tumor cells, but it is not expressed, thus rendering these cells resistant to anti-viral therapeutics. (Sourced from: https://www.prnewswire.com/news-releases/hemaquest-pharmaceuticals-initiates-phase-2-clinical-trial-in-ebv-related-malignancies-100425419.html)
Mechanisms of Action: Fatty Acid
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: HemaQuest
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Lymphoproliferative Disorders|Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00992732 |
HQP-1004-EB-03 | P2 |
Terminated |
Lymphoproliferative Disorders |
2010-11-01 |
2019-03-19 |
Treatments |
|
NCT00917826 |
P2 L-D AB | P2 |
Terminated |
Lymphoma|Lymphoproliferative Disorders |
2009-09-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|